Caitong International Asset Management’s Rein Therapeutics RNTX Stock Holding History

Caitong International Asset Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4	Buy	+3	New	+$4	﹤0.01%	2361

Other funds holding RNTX

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Caitong International Asset Management's RNTX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Rein Therapeutics (RNTX) in Q1 2026: 3 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #2361 among its holdings.

46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

Caitong International Asset Management held 3 shares of Rein Therapeutics worth $4 as of Q1 2026.
Rein Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Rein Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2361 holding.
46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.